Literature DB >> 11936371

Cephalosporins in surgical prophylaxis.

S Geroulanos1, K Marathias, J Kriaras, B Kadas.   

Abstract

Controlled clinical trials have shown that antimicrobial prophylaxis can lower the incidence of infection after certain operations, thus reducing morbidity, hospital stay, antibiotic usage and mortality due to sepsis. An effective prophylactic regimen should be directed against the most likely infecting organisms, but need not be active against every potential pathogen. Infection can be prevented when effective concentrations are present in the blood and the tissue during and shortly after the procedure. Therefore, antimicrobial prophylaxis should begin just before the operation: beginning earlier is unnecessary and potentially dangerous, beginning later is less effective. A single-dose prophylaxis after the induction of anesthesia is sufficient. If surgery is delayed or prolonged, a second dose is advisable if an antimicrobial drug with a short half-life is used. Postoperative administration is unnecessary and is harmful. Cephalosporins are considered to be the drug of choice, because they offer fewer allergic reactions. From the first generation cephalosporins, cefazolin has been widely recommended with success. From the second generation cephalosporins, cefuroxime, cefamandole and cefoxitin are increasingly recommended. Their antistaphylococcal activity is somewhat less strong but their activity against gram-negative bacteria is stronger. In addition, cefoxitin has good activity against anaerobes. Third generation cephalosporins, such as cefotaxime, cefoperazone, ceftriaxone, ceftazidime or ceftizoxime are generally not recommended for surgical prophylaxis. Despite these recommendations, they have been accepted by the medical community and are today in use in many countries as the most common drugs in surgical prophylaxis. Ceftriaxone in particular, is far exceeding the sales of any other drug for prophylaxis. Contra-indications, limitations, additional or other drugs and practical recommendations for specific procedures are discussed and the results of several prospective randomized studies are presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11936371     DOI: 10.1179/joc.2001.13.Supplement-2.23

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  13 in total

1.  Commentary on transoral access for endoscopic thyroid resection : Witzel K, von Rahden BH, Kaminski C, Stein HJ (2008) Transoral access for endoscopic thyroid resection. Surg Endosc 22(8):1871-1875.

Authors:  Gianlorenzo Dionigi; Francesca Rovera; Luigi Boni
Journal:  Surg Endosc       Date:  2008-12-06       Impact factor: 4.584

2.  A Critical Evaluation and Comparison of Antimicrobial Prophylaxis in Elective Surgeries Across three Hospitals.

Authors:  Yogesh Belagali; Alwar Mc; Poornachandra Thejeswi; Ullal Sheetal D; Vani Bhagwath; Ashok Shenoy K; Mukta Chowta; Sahana D Acharya
Journal:  J Clin Diagn Res       Date:  2013-06-01

3.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

Authors:  Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 5.  Microbiology and management of abdominal infections.

Authors:  Itzhak Brook
Journal:  Dig Dis Sci       Date:  2008-02-21       Impact factor: 3.199

6.  Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial.

Authors:  John Blomberg; Pernilla Lagergren; Lena Martin; Fredrik Mattsson; Jesper Lagergren
Journal:  BMJ       Date:  2010-07-02

7.  Comparative evaluation of prophylactic single-dose intravenous antibiotic with postoperative antibiotics in elective urologic surgery.

Authors:  Mohammad K Moslemi; Seyed M Moosavi Movahed; Akram Heidari; Hossein Saghafi; Mehdi Abedinzadeh
Journal:  Ther Clin Risk Manag       Date:  2010-11-09       Impact factor: 2.423

8.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.

Authors:  Lorna E T Stearne; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

10.  Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial.

Authors:  Edin Mujagic; Tibor Zwimpfer; Walter R Marti; Marcel Zwahlen; Henry Hoffmann; Christoph Kindler; Christoph Fux; Heidi Misteli; Lukas Iselin; Andrea Kopp Lugli; Christian A Nebiker; Urs von Holzen; Fabrizio Vinzens; Marco von Strauss; Stefan Reck; Marko Kraljević; Andreas F Widmer; Daniel Oertli; Rachel Rosenthal; Walter P Weber
Journal:  Trials       Date:  2014-05-24       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.